TABLE 2.
Indicates the assessment was attempted but needed to be modified or performed partially when conducted remotely due to safety and/or handling expertise required. ^ Indicates the assessment can be feasible with standardized equipment and/or sufficient space within home which may not be available for some visits. DMD: Duchenne muscular dystrophy; BMD: Becker muscular dystrophy; SMA: spinal muscular atrophy; LGMD: limb girdle muscular dystrophy; CMD: Congenital muscular dystrophies; HMERF: Hereditary myopathy with early respiratory failure; LAMA2: laminin-2 related muscular dystrophy; FSHD: facioscapulohumeral dystrophy; CMS: congenital myasthenic syndromes; SMARD1: SMA with respiratory distress; POM: Pompe disease; MYO: Myotonic dystrophy; VCP: valosin containing protein associated multisystem proteinopathy; NSAA: North Star Ambulatory Assessment; NSAD: North Star Assessment for limb girdle-type dystrophies; TFT: Timed functional tests including rise from floor, 10 m walk/run; Neuromuscular GRO: Neuromuscular Gross Motor Outcome; Bayley: Bayley scales of infant and toddler development–gross motor subtest; MFM: Motor Function Measure; RHS: Revised Hammersmith Scale; HFMSE: Hammersmith Functional Motor Scales Expanded; CHOP Intend: Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; RULM: Revised Upper Limb Module; EK2: Egen Klassifikation two; Brooke: Brooke Upper Extremity Functional Rating Scale; PUL: Performance of Upper Limb; Vignos: Vignos Lower Extremity Rating Scale; TUG: Timed Up and Go; PROM: Patient report outcome measure; 9HPT: Nine hole peg test.